619-20-5

Usage

Uses

Used in Pharmaceutical Industry:
3-Ethylbenzoic acid is used as a synthetic intermediate for the preparation of bi-aryl amines. These bi-aryl amines act as M3 muscarinic acetylcholine receptor antagonists, which are crucial in the development of drugs targeting various medical conditions, such as overactive bladder, irritable bowel syndrome, and chronic obstructive pulmonary disease (COPD). 3-ETHYLBENZOIC ACID's ability to form bi-aryl amines with specific receptor antagonist properties makes it a valuable component in the pharmaceutical industry.
Used in Chemical Synthesis:
3-Ethylbenzoic acid serves as a key building block in the synthesis of various organic compounds, including dyes, fragrances, and agrochemicals. Its unique structural features allow for a range of chemical reactions, such as esterification, amidation, and halogenation, which can be exploited to produce a diverse array of products. This versatility makes 3-ethylbenzoic acid an essential component in the chemical synthesis industry.
Used in Research and Development:
Due to its unique chemical properties and potential applications, 3-ethylbenzoic acid is often utilized in research and development for the discovery of new compounds and materials. It can be employed as a starting material or a reagent in various chemical reactions, enabling scientists to explore novel synthetic pathways and develop innovative products with improved properties and applications.

InChI:InChI=1/C9H10O2/c1-2-7-4-3-5-8(6-7)9(10)11/h3-6H,2H2,1H3,(H,10,11)

Upstream product

• 34136-57-7 m-ethylbenzonitrile 
• 141-93-5 m-diethylbenzene 
• 124-38-9 carbon dioxide 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 623-13-2 4-methylphenyl methylsulfide 
• 100-47-0 benzonitrile 
• 587-02-0 m-ethylaniline 
• 2725-82-8 1-bromo-3-ethylbenzene 
• 97-94-9 triethyl borane 
• 585-76-2 m-bromobenzoic acid 
• 620-14-4 1-Methyl-3-ethylbenzene 
• 71-43-2 benzene 
• 500293-87-8 3-ethylbenzamide 
• 100-41-4 ethylbenzene 

Downstream Products

• 22699-70-3 3-ethylacetophenone 
• 35193-44-3 3-ethyl-2-nitrobenzoic acid 
• 82657-69-0 (3-ethylphenyl)methanol 
• 5437-40-1 2-amino-3-ethylbenzoic acid 
• 1064205-33-9 2-(3-ethylbenzoyl)-3-methyl-6-benzyloxy-7-methoxy-1,2,3 ,4-tetrahydroisoquinoline 
• 216658-62-7 1-(bromomethyl)-3-ethylbenzene 
• 1064205-39-5 (+/-)-2-(3-ethylbenzyl)-6-hydroxy-7-methoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline 
• 1064205-37-3 (+/-)-6-benzyloxy-2-(3-ethylbenzyl)-7-methoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline 
• 1000896-43-4 5-[(3-ethylphenyl)methoxy]-2H-pyrazol-3-amine 
• 50604-00-7 methyl ester of 3-ethylbenzoic acid 
• 71527-31-6 3-ethylbenzoyl chloride 

Relevant academic research and scientific papers

Palladium aminopyridine complexes catalyzed selective benzylic C-H oxidations with peracetic acid

Four palladium(ii) complexes with tripodal ligands of the tpa family (tpa = tris(2-pyridylmethyl)amine) have been synthesized and X-ray characterized. These complexes efficiently catalyze benzylic C-H oxidation of various substrates with peracetic acid, affording the corresponding ketones in high yields (up to 100%), at 1 mol% catalyst loadings. Complex [(tpa)Pd(OAc)](PF6) with the least sterically demanding ligand tpa demonstrates the highest substrate conversions and ketone selectivities. Preliminary mechanistic data provide evidence in favor of metal complex-mediated rate-limiting benzylic C-H bond cleavage by an electron-deficient oxidant.

Inclusion complex containing epoxy resin composition for semiconductor encapsulation

The invention is an epoxy resin composition for sealing a semiconductor, including (A) an epoxy resin and (B) a clathrate complex. The clathrate complex is one of (b1) an aromatic carboxylic acid compound, and (b2) at least one imidazole compound represented by formula (II): wherein R2 represents a hydrogen atom, C1-C10 alkyl group, phenyl group, benzyl group or cyanoethyl group, and R3 to R5 represent a hydrogen atom, nitro group, halogen atom, C1-C20 alkyl group, phenyl group, benzyl group, hydroxymethyl group or C1-C20 acyl group. The composition has improved storage stability, retains flowability when sealing, and achieves an effective curing rate applicable for sealing delicate semiconductors.

B-Alkyl Suzuki-Miyaura cross-coupling of tri-n-alkylboranes with arylbromides bearing acidic functions under mild non-aqueous conditions

An efficient and chemoselective Pd-catalyzed B-alkyl Suzuki-Miyaura cross-coupling of tri-n-alkylboranes with arylbromides possessing acidic functions is described. This protocol features the relatively weak base Cs2CO3 and mild non-

Direct B-alkyl Suzuki-Miyaura cross-coupling of trialkyl-boranes with aryl bromides in the presence of unmasked acidic or basic functions and base-labile protections under mild non-aqueous conditions

An efficient and chemoselective palladium-catalyzed direct B-alkyl Suzuki-Miyaura cross-coupling of trialkylboranes with diversely functionalized aryl bromides is described. A wide variety of unmasked acidic or basic functions are tolerated. The mild non-

Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

MEDICINAL COMPOSITIONS

The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

Substituted 1,3-thiazole compounds, their production and use

(1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.

NEW COMPOUNDS

The present invention relates to new compounds of formula I, (I) a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

JNK INHIBITOR

The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.